Skip to content
Thursday 13 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,799.94
-0.31%
DAX
26,439.80
+0.41%
CAC 40
8,695.00
+0.23%
STOXX 50
6,563.67
+0.45%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Conference

  • ThetaRay Gamifies Financial Defense at Money20/20 Europe with a Compliance Twist on “Where’s Waldo”

    June 2, 2026

    With “Spot The Money Mule”, ThetaRay unites Agentic AI and public education to disrupt criminal recruitment; pushing for an ecosystem-wide stand against illicit finance.

  • Bidgely’s EmPOWER AI London Convenes Leaders to Map the Future of Electrification, Load Flexibility, Customer Experience and Energy Affordability

    May 28, 2026

    New LCP Delta report anchors an interactive agenda, driving candid conversations with independent researchers and regional visionaries

  • Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

    May 27, 2026

    Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the [...]

  • Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

    May 26, 2026

    — Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —

  • Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

    May 21, 2026

    – Real-World Evidence of Positive Impact of LYBALVI® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative Symptoms and Outcomes From Four Years of Treatment, and Real-World Evidence From Use of LYBALVI (olanzapine and samidorphan) in Clinical Practice –

  • Xsolla and the Dubai Films and Games Commission Create a Strategic Partnership to Connect Dubai-Based Developers to Global Markets

    May 21, 2026

    Multi-Year Agreement Creates Opportunities to Build All The Things for Video Games in Dubai and MENA

  • Xsolla Expands Nordic Presence With Industry Engagements Across Sweden, Including Official Sponsorship of Nordic Game 2026

    May 20, 2026

    Coordinated Activations Across Sweden Underscore Xsolla’s Continued Investment In The Nordic Games Ecosystem, Bringing Developers, Partners, And Creators Together

  • LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

    May 19, 2026

    LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on [...]

  • Money20/20 Europe Announces Powerhouse Speaker Lineup Featuring Leaders from Klarna, BBVA, ABN AMRO, Mastercard, eToro, and Revolut

    May 19, 2026

    Leading voices in payments, banking, and fintech innovation to take the stage in Amsterdam

  • AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

    May 14, 2026

    Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 Preclinical data show AVB-406 achieved up to 80% MAPT/tau knockdown in the brain

Posts pagination

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • …
  • Page 13
  • Next

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

  • As it happened: Stocks jittery as oil nears $90; Trump ‘semi-negotiating’ with Iran

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook